| Autor: |
Roodhart JM; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., He H, Daenen LG, Monvoisin A, Barber CL, van Amersfoort M, Hofmann JJ, Radtke F, Lane TF, Voest EE, Iruela-Arispe ML |
| Jazyk: |
angličtina |
| Zdroj: |
Blood [Blood] 2013 Jul 04; Vol. 122 (1), pp. 143-53. Date of Electronic Publication: 2013 May 20. |
| DOI: |
10.1182/blood-2012-11-459347 |
| Abstrakt: |
Host responses to chemotherapy can induce resistance mechanisms that facilitate tumor regrowth. To determine the contribution of bone marrow-derived cells (BMDCs), we exposed tumor-bearing mice to chemotherapeutic agents and evaluated the influx and contribution of a genetically traceable subpopulation of BMDCs (vascular endothelial-cadherin-Cre-enhanced yellow fluorescent protein [VE-Cad-Cre-EYFP]). Treatment of tumor-bearing mice with different chemotherapeutics resulted in a three- to 10-fold increase in the influx of VE-Cad-Cre-EYFP. This enhanced influx was accompanied by a significant increase in angiogenesis. Expression profile analysis revealed a progressive change in the EYFP population with loss of endothelial markers and an increase in mononuclear markers. In the tumor, 2 specific populations of VE-Cad-Cre-EYFP BMDCs were identified: Gr1⁺/CD11b⁺ and Tie2high/platelet endothelial cell adhesion moleculelow cells, both located in perivascular areas. A common signature of the EYFP population that exits the bone marrow is an increase in Notch. Inducible inactivation of Notch in the EYFP⁺ BMDCs impaired homing of these BMDCs to the tumor. Importantly, Notch deletion reduced therapy-enhanced angiogenesis, and was associated with an increased antitumor effect of the chemotherapy. These findings revealed the functional significance of a specific population of supportive BMDCs in response to chemotherapeutics and uncovered a new potential strategy to enhance anticancer therapy. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
